Business Wire

causaLens launches the first causal AI platform

22.9.2020 16:00:00 EEST | Business Wire | Press release

Share

causaLens , a deep-tech company predicting and optimising the global economy, has released the World’s first causal Artificial Intelligence (causal AI) enterprise platform. Businesses no longer have to rely on curve-fitting machine learning platforms unable to handle the complexity of today's world. They are invited to join the real AI revolution with a platform that understands cause and effect.

The causaLens platform defines a new category of machine intelligence. Its next generation AI engine harnesses an understanding of cause and effect relationships to directly optimise business KPIs.

“Businesses investing in the current form of machine learning (ML), including AutoML, have just been paying to automate a process that fits curves to data without an understanding of the real world. They are effectively driving forward by looking in the rear-view mirror,” explains causaLens CEO Darko Matovski. “Our platform takes a radically different approach. Causal AI teaches machines to understand cause and effect, a necessary step to developing true AI. This allows our platform to autonomously operate at a new level of abstraction that explains to businesses what actions they need to take to achieve their objectives.”

causaLens has a track record of breaking new ground, having pioneered automated machine learning (AutoML) for time series data. The causal AI platform retains the advantages of comprehensive automation, allowing thousands of data sets to be cleaned, sorted and monitored at the same time. However, it combines it with causal models and insights that are truly explainable - traditionally the sole province of domain experts. Unique human knowledge is harnessed through intuitive interfaces for human-machine partnerships.

Since its inception in 2017, causaLens has worked with a range of corporates across multiple industries. Customers include some of the world’s largest Asset Managers, Hedge Funds, Tier-1 Investment Banks, Transportation and Logistics companies, and Energy and Commodity traders.

Masami Johnstone, Head of Information Services at CLS, whose products help clients navigate the changing Foreign Exchange marketplace, said: "The causaLens platform has enabled us to discover additional value in our data. Their causal AI technology autonomously finds valuable signals in huge datasets and has helped us to understand relationships between our data and other datasets.”

Today’s world is changing faster than ever before. Current state of the art ML barely scratches the surface of what machines can do. Causal AI is the next huge step forward.

Demonstrations of the product can be requested via causaLens.com.

causaLens

causaLens is pioneering Causal AI, a new category of intelligent machines that understand cause and effect - a major step towards true AI. Its enterprise platform is used to transform leading businesses in Finance, IoT, Energy, Telecommunications and others.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Darko Matovski,
CEO and co-founder
E: darko@causalens.com
www.causaLens.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release

VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release

Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye